Cytomegalovirus seroprevalence and 'cytomegalovirus-safe' seropositive blood donors

Epidemiology and Infection

Volumn 137, Issue 12, 2009, Pages 1776-1780

  Badami, K G ^a   McQuilkan Bickerstaffe, S ^a   Wells, J E ^b   Parata, M ^a  

^a New Zealand Blood Service   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cytomegalovirus; Estimating; Prevalence of disease; Transfusion associated infections

Indexed keywords

ADULT; AGE; AGED; ARTICLE; ASIAN; BLOOD DONOR; CAUCASIAN; CYTOMEGALOVIRUS; ETHNICITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAORI; NEW ZEALAND; PACIFIC ISLANDER; SEROCONVERSION; SEROPREVALENCE; SEX DIFFERENCE; BLOOD; CYTOMEGALOVIRUS INFECTION; EPIDEMIOLOGY; MIDDLE AGED; TIME;

ADULT; AGED; BLOOD DONORS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; SEROEPIDEMIOLOGIC STUDIES; TIME; YOUNG ADULT;

EID: 70449720906     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268809990094     Document Type: Article

References (19)

1. Nichols WG, et al. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003; 101: 4195-4200.
2. Vamvakas EC. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion ? A review of the literature and meta-analysis. Transfusion Medicine Reviews 2005; 19: 181-199.
3. Bowden RA, et al. A comparison of filtered leukocytereduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusiontransmitted CMV infection after marrow transplant. Blood 1995; 86: 3598-3603.
4. Laupacis A, et al. Prevention of posttransfusion CMV in the era of universal WBC reduction : a consensus statement. Transfusion 2001; 41: 560-569.
5. Onorato IM, et al. Epidemiology of human cytomegaloviral infections : recommendations for prevention and control. Reviews of Infectious Diseases 1985; 7: 479-497.
6. Krech U. Complement fixing antibodies against cytomegalovirus in different parts of the world. Bulletin of the World Health Organization 1973; 49: 103-106.
7. Dowd JB, Aiello AE, Alley DE. Socioeconomic disparities in the seroprevalence of cytomegalovirus infection in the US population: NHANES III. Epidemiology and Infection 2009; 137: 58-65.
8. Bayer WL, Tegtmeier GE. The blood donor: detection and magnitude of cytomegalovirus carrier states and the prevalence of cytomegalovirus antibody. Yale Journal of Biology and Medicine 1976; 49: 5-12.
9. Beresford CH, et al. Cytomegalovirus infection and blood transfusion. New Zealand Medical Journal 1988; 101: 2-4.
10. Drew WL, et al. Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients. Transfusion 2003; 43: 309-313.
11. Ziemann M, et al. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion 2007; 47: 1972-1983.
12. Seale H, et al. National serosurvey of cytomegalovirus in Australia. Clinical and Vaccine Immunology 2006; 13: 1181-1184.
13. Pamphilon DH, et al. Prevention of transfusiontransmitted cytomegalovirus infection. TransfusionMedicine 1999; 9: 115-123.
14. Lee PI, et al. Changing seroepidemiological patterns of cytomegalovirus infection in children in Taiwan from 1984 to 1989. Journal of Medical Virology 1992; 36: 75-78.
15. Statistics New Zealand. (http://www.stats.govt.nz/ products-and-services/ Articles/pop-proj-Jun04.htm). Accessed 23 March 2009.
16. Statistics New Zealand. (http://www.stats.govt.nz/NR/ rdonlyres/0E22AC6C-C4BD-4AD3-969C-F762EBA0 ADFD/0/ SoFIEwealthdisparityeditedfinal-amended 11May05-pdf). Accessed 23 March 2009.
17. de Ory F, et al. Is there a change in cytomegalovirus seroepidemiology in Spain? European Journal of Epidemiology 2004; 19: 85-89.
18. Hecker M, et al. Continuous cytomegalovirus seroconversion in a large group of healthy blood donors. Vox Sanguinis 2004; 86: 41-44.
19. Roback JD. CMV and blood transfusions. Reviews in Medical Virology 2002; 12: 211-219.